Advanced bladder cancer treatment has changed so quickly that an oncology textbook can feel slightly out of date before the ink finishes drying. Platinum chemotherapy remains valuable, but it is no longer the only serious player on the field. Immunotherapies, antibody-drug conjugates, targeted medicines, molecular testing, and blood-based monitoring are reshaping how doctors approach muscle-invasive, locally advanced, and metastatic bladder cancer.

The changes matter because bladder cancer is still a major health problem. The American Cancer Society estimates that the United States will record about 84,530 new bladder cancer cases and 17,870 deaths in 2026. Most bladder tumors are urothelial carcinomas, which may begin in the bladder or elsewhere along the urinary tract.

This overview examines the most important treatment updates available through August 4, 2026, including newer first-line combinations, biomarker-driven therapy, perioperative treatment, circulating tumor DNA testing, and clinical studies that may influence the next generation of care.

What Does “Advanced Bladder Cancer” Mean?

The term advanced bladder cancer can describe several different situations. Muscle-invasive bladder cancer has grown into the bladder’s muscular wall. Locally advanced disease has extended into nearby tissues or lymph nodes. Metastatic urothelial carcinoma has traveled to distant organs, commonly the lungs, liver, bones, or distant lymph nodes.

These categories are important because they do not share one universal treatment plan. A patient whose cancer can still be removed surgically may receive therapy before and after cystectomy. Someone with unresectable or metastatic disease usually needs systemic treatment that circulates throughout the body. Treatment goals may include curing the disease, delaying recurrence, shrinking tumors, controlling symptoms, extending survival, or preserving quality of life.

Enfortumab Vedotin Plus Pembrolizumab Changed First-Line Care

The most influential recent development in metastatic urothelial cancer is the combination of enfortumab vedotin and pembrolizumab. Enfortumab vedotin is an antibody-drug conjugate that recognizes nectin-4, a protein commonly found on urothelial cancer cells. It carries a cell-killing medicine directly toward those cells. Pembrolizumab is an immune checkpoint inhibitor that blocks PD-1, helping immune cells recognize and attack cancer.

Why the EV-302 Results Were So Important

In the phase 3 EV-302 trial, 886 previously untreated patients with locally advanced or metastatic urothelial carcinoma received either enfortumab vedotin plus pembrolizumab or platinum-based chemotherapy. Median progression-free survival was 12.5 months with the combination and 6.3 months with chemotherapy. Median overall survival was 31.5 months versus 16.1 months, respectively.

The confirmed response rate was 67.7% with enfortumab vedotin plus pembrolizumab, and 29.1% of evaluated patients achieved a complete response on imaging. The results were strong across major subgroups, including patients who were eligible or ineligible for cisplatin and those with different PD-L1 expression levels. The FDA approved the combination for locally advanced or metastatic urothelial cancer in December 2023.

The Combination Is Powerful, Not Effortless

Better outcomes do not mean an easy ride. Enfortumab vedotin can cause skin reactions, peripheral neuropathy, elevated blood sugar, eye problems, and, less commonly, serious lung inflammation. Pembrolizumab may trigger immune-related inflammation affecting the thyroid, lungs, liver, intestines, kidneys, skin, or other organs.

Early reporting is crucial. A rash that appears “annoying but manageable” on Monday can become a much bigger problem by Friday. Doctors may pause treatment, reduce the enfortumab dose, prescribe corticosteroids for immune complications, or discontinue one part of the combination while continuing the other.

Nivolumab Plus Cisplatin and Gemcitabine Offers Another First-Line Option

For patients able to receive cisplatin, another FDA-approved first-line approach combines nivolumab with gemcitabine and cisplatin, followed by nivolumab maintenance. Nivolumab is another PD-1 checkpoint inhibitor.

In the CheckMate 901 study, the nivolumab combination produced a median overall survival of 21.7 months, compared with 18.9 months for cisplatin and gemcitabine alone. Median progression-free survival was 7.9 months versus 7.6 months. Although the difference in median progression-free survival appears modest, the trial demonstrated statistically significant improvements in survival and disease control, leading to FDA approval in March 2024.

This option is especially relevant when a patient is considered fit for cisplatin and the oncology team prefers a chemotherapy-immunotherapy strategy. Kidney function, hearing, nerve health, heart function, daily activity level, and other medical conditions all influence cisplatin eligibility. Cisplatin is effective, but it does not exactly arrive carrying a basket of muffins.

Platinum Chemotherapy and Avelumab Maintenance Still Matter

Not every patient will receive enfortumab vedotin plus pembrolizumab. Existing neuropathy, uncontrolled diabetes, severe skin disease, access limitations, previous immune complications, or other health concerns may make a different sequence more appropriate.

Platinum-based chemotherapy followed by avelumab maintenance remains an established approach for patients whose cancer does not progress during four to six cycles of cisplatin- or carboplatin-based chemotherapy. In the JAVELIN Bladder 100 trial, switching promptly to avelumab maintenance improved overall survival compared with supportive care alone. The important word is maintenance: doctors do not necessarily wait for visible progression before starting the immunotherapy.

This strategy can still be useful when chemotherapy produces a good response, when an antibody-drug conjugate is unsuitable, or when treatment sequencing requires greater flexibility. Modern bladder cancer care is becoming less like choosing a single winner and more like planning several moves ahead.

FGFR3 Testing Can Open the Door to Erdafitinib

Molecular testing is increasingly central to advanced bladder cancer treatment. Some urothelial tumors contain alterations in FGFR3, a gene involved in cell growth and signaling. These changes can make the cancer susceptible to the oral targeted drug erdafitinib.

In the phase 3 THOR trial, erdafitinib was compared with chemotherapy in previously treated patients whose metastatic urothelial cancers carried eligible FGFR alterations. Median overall survival was 12.1 months with erdafitinib and 7.8 months with chemotherapy. Median progression-free survival was 5.6 months versus 2.7 months. These findings supported full FDA approval in January 2024 for appropriately selected patients with susceptible FGFR3 alterations after prior systemic treatment.

Erdafitinib has a distinctive safety profile. It can raise phosphate levels, cause mouth sores, diarrhea, nail and skin changes, and produce retinal or other eye problems. Patients generally need regular blood testing and scheduled eye examinations. The drug is a good example of why genomic testing should be performed early enough for the results to be useful rather than ordered when everyone is already sprinting toward the next decision.

HER2-Targeted Therapy Is Expanding the Research Map

HER2 is best known for its role in breast and gastric cancers, but some urothelial cancers also express high levels of the protein. In April 2024, the FDA granted a tumor-agnostic accelerated approval to fam-trastuzumab deruxtecan for previously treated, unresectable or metastatic solid tumors with HER2 IHC 3+ expression when no satisfactory alternative treatment exists.

This approval can include qualifying urothelial tumors, although eligibility depends on precise HER2 testing and the patient’s treatment history. Trastuzumab deruxtecan can cause serious interstitial lung disease or pneumonitis, making prompt evaluation of new coughing, shortness of breath, or fever essential.

Disitamab Vedotin Studies

Another HER2-directed antibody-drug conjugate, disitamab vedotin, is being tested alone and with immune checkpoint inhibitors. A phase 3 study is comparing disitamab vedotin plus pembrolizumab with platinum chemotherapy in previously untreated, HER2-expressing locally advanced or metastatic urothelial carcinoma. The trial enrolled tumors with HER2 expression of IHC 1+ or higher, potentially creating a broader target population than therapies limited to IHC 3+ disease.

Separate research has examined disitamab vedotin with toripalimab. These trials are testing whether an antibody-drug conjugate and immunotherapy can produce complementary effects similar to those seen with enfortumab vedotin and pembrolizumab. Promising research results are exciting, but they should not be mistaken for automatic U.S. approval. The regulatory finish line remains a finish line, not a decorative suggestion.

One Treatment Update Was Actually a Withdrawal

Progress in cancer medicine includes learning when a treatment does not deliver the expected confirmatory benefit. Sacituzumab govitecan previously had accelerated approval for certain patients with advanced urothelial cancer after platinum chemotherapy and PD-1 or PD-L1 treatment. The FDA announced the final withdrawal of that urothelial cancer indication in November 2024.

The drug may still be studied in clinical trials and remains approved for certain other cancers, but it is no longer FDA-approved for the withdrawn urothelial carcinoma indication. This distinction is important when reading older articles, treatment charts, or online discussion boards that have not been updated since the era when everyone was still disinfecting their groceries.

Advanced Treatments Are Moving Into Earlier-Stage Disease

Some of the biggest bladder cancer updates in 2025 and 2026 involve using successful metastatic therapies earlier, when cure may still be possible.

Perioperative Enfortumab Vedotin and Pembrolizumab

In November 2025, the FDA approved perioperative enfortumab vedotin plus pembrolizumab for cisplatin-ineligible adults with muscle-invasive bladder cancer. Treatment is given before cystectomy and continued after surgery. The KEYNOTE-905/EV-303 trial showed significant improvements in event-free and overall survival compared with surgery alone.

On July 10, 2026, the FDA expanded this perioperative strategy to all adults with muscle-invasive bladder cancer who are candidates for cystectomy. In the KEYNOTE-B15/EV-304 trial, the regimen was compared with neoadjuvant gemcitabine and cisplatin. Event-free survival and overall survival were significantly improved with perioperative enfortumab vedotin and pembrolizumab. The expansion means cisplatin eligibility is no longer required for this particular FDA-approved perioperative use.

Circulating Tumor DNA Begins Guiding Adjuvant Treatment

Another major 2026 development was the use of circulating tumor DNA molecular residual disease testing, often shortened to ctDNA MRD. Tiny fragments of tumor-derived DNA may remain detectable in the blood after surgery even when scans show no visible cancer.

In May 2026, the FDA approved atezolizumab as adjuvant treatment for adults with muscle-invasive bladder cancer who have ctDNA-detected molecular residual disease after cystectomy. In IMvigor011, median disease-free survival was 9.9 months with atezolizumab and 4.8 months with placebo. Median overall survival was 32.8 months versus 21.1 months. The FDA also authorized a companion diagnostic to identify eligible patients.

This represents a larger shift toward treating biological evidence of residual cancer before conventional imaging can find a tumor. It may also help spare some ctDNA-negative patients from immediate additional therapy, although surveillance schedules and individual risk factors still require specialist interpretation.

Clinical Studies That Could Shape the Next Treatment Era

Next-Generation Antibody-Drug Conjugates

Researchers are testing antibody-drug conjugates aimed at HER2, TROP2, nectin-4, and other tumor-associated proteins. The objective is easy to describe but difficult to execute: deliver a potent payload to cancer cells while reducing damage to healthy tissue. Newer studies are also examining dual-targeting molecules and combinations designed to overcome resistance after earlier antibody-drug conjugates.

Better Biomarkers for Treatment Selection

PD-L1 alone has not been a perfect treatment compass in urothelial cancer. Current research is evaluating FGFR alterations, HER2 expression, ctDNA, tumor mutational burden, gene-expression patterns, immune-cell signatures, and combinations of biomarkers. The long-term goal is to answer a practical question: which treatment is most likely to help this patient, rather than which treatment helped the average patient in a large trial?

Smarter Sequencing

As more therapies move into first-line and perioperative care, doctors need evidence about what should come next. A person who progresses after enfortumab vedotin plus pembrolizumab may still receive platinum chemotherapy. Someone with an FGFR3 alteration may later receive erdafitinib. HER2-directed therapy or a clinical trial may be appropriate for selected patients.

However, the best sequence is not always known because many older studies enrolled patients before today’s combinations became standard. New trials must answer modern questions using modern treatment histories. Comparing a new drug with a control arm from yesterday’s playbook is no longer enough.

Bladder Preservation and Minimal Residual Disease

Studies are also exploring whether selected patients with muscle-invasive disease can safely avoid immediate bladder removal after an excellent response to systemic treatment. Other trials use ctDNA to escalate treatment for patients at high risk or reduce unnecessary therapy for those at lower risk. NCI trial listings reflect broad research activity involving immunotherapy, radiation, targeted drugs, antibody-drug conjugates, and biomarker-guided strategies.

Questions Patients Can Ask Their Oncology Team

• Has my tumor been tested for FGFR3 alterations and HER2 expression?
• Am I eligible for enfortumab vedotin plus pembrolizumab?
• Would cisplatin-based chemotherapy be safe given my kidney, hearing, nerve, and heart health?
• Could platinum chemotherapy followed by avelumab maintenance be appropriate?
• Which side effects should trigger an urgent phone call?
• Should I consider a clinical trial now rather than after several more treatments?
• Could ctDNA testing affect treatment or surveillance after surgery?
• How will the plan protect mobility, nutrition, sleep, independence, and daily quality of life?

Conclusion

The advanced bladder cancer treatment landscape is more hopeful and more complicated than it was only a few years ago. Enfortumab vedotin plus pembrolizumab has established a new first-line benchmark for many patients with locally advanced or metastatic urothelial carcinoma. Nivolumab with cisplatin and gemcitabine offers another evidence-based first-line option, while platinum chemotherapy followed by avelumab remains clinically important.

Molecular testing can identify patients who may benefit from erdafitinib or HER2-directed therapy. Meanwhile, perioperative antibody-drug conjugate combinations and ctDNA-guided immunotherapy are bringing precision treatment into earlier-stage disease. The result is not a simple menu but a branching decision tree shaped by tumor biology, previous therapy, organ function, symptoms, personal priorities, and access to specialized care.

Patient and Caregiver Experience: What Treatment Can Feel Like

The experience of advanced bladder cancer treatment often begins with a surprising amount of waiting. There is waiting for pathology, imaging, molecular test results, insurance authorization, infusion appointments, and the next scan. Then, suddenly, everything happens at once. A patient may have blood drawn, meet the oncologist, speak with an infusion nurse, receive several medicines, and leave carrying a calendar that looks as though it was designed by an air-traffic controller.

Many people discover that treatment is not divided neatly into “good days” and “bad days.” Fatigue may arrive two days after an infusion rather than immediately. Appetite can change from one cycle to another. Tingling in the fingers may begin subtly, making buttons, zippers, or phone screens unexpectedly irritating. Immune-related symptoms may appear after weeks or months of apparently smooth treatment. Keeping a daily symptom record can help patients notice patterns and describe changes accurately.

Skin care is especially important during enfortumab-containing treatment. Patients may be advised to watch for redness, peeling, blistering, pain, or rapidly spreading rashes. Peripheral neuropathy deserves equal attention. Reporting numbness early is not complaining; it is providing information that may prevent lasting nerve damage. Dose reductions and treatment pauses are often tools for continuing care safely, not signs that a patient has somehow failed oncology class.

Emotional reactions also fluctuate. Scan anxiety can begin days before imaging and peak while waiting for results. A partial response may bring relief mixed with fear about how long it will last. Stable disease can feel anticlimactic until someone explains that stopping an aggressive cancer from growing may be a meaningful victory. Support groups, oncology social workers, counselors, spiritual-care providers, and trusted friends can help patients process uncertainty without requiring them to perform optimism around the clock.

Caregivers frequently become unofficial project managers. They track medications, transportation, nutrition, appointment notes, and emergency phone numbers. A shared digital calendar and one-page medication list can reduce confusion. It is also helpful to decide who will receive medical updates and who will handle practical tasks such as meals, insurance calls, or childcare. “Let us know how we can help” becomes much more useful when converted into “Please drive us Tuesday” or “Could you bring dinner Thursday?”

Patients may benefit from asking about palliative care early. Palliative care is not the same as stopping cancer treatment. It can be provided alongside active therapy to address pain, urinary symptoms, fatigue, nausea, sleep problems, anxiety, mobility, and family stress. The aim is to make living with treatment more manageable, not to wave a white flag.

The most useful experience-based lesson is that treatment plans should remain adjustable. A therapy that looks ideal on paper may need modification after side effects emerge. Another option may become available when molecular results return or a clinical trial opens. Successful care often depends on frequent communication, realistic expectations, and a team willing to adapt before a manageable problem turns into an emergency.